How does fingolimod (gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?

Frontiers in Neurology

Volumn 4 MAY, Issue , 2013, Pages

  Fazekas, Franz ^a   Bajenaru, Ovidiu ^b   Berger, Thomas ^c   Fabjan, Tanja Hojs ^d   Ledinek, Alenka Horvat ^e   Jakab, Gábor ^f   Komoly, Samuel ^g   Kobys, Tetiana ^h   Kraus, Jörg ⁱ   Kurča, Egon ^j   Kyriakides, Theodoros ^k   Lisý, L'ubomír ^l   Milanov, Ivan ^m   Nehrych, Tetyana ⁿ   Moskovko, Sergii ^o   Panayiotou, Panayiotis ^p   Jazbec, Saša Šega ^e   Sokolova, Larysa ^q   Taláb, Radomír ^r   Traykov, Latchezar ^m   Turčáni, Peter ^s   Vass, Karl ^t   Vella, Norbert ^u   Voloshyná, Nataliya ^v   Havrdová, Eva ^w   more..

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^e UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^f UZSOKI HOSPITAL   (Hungary)

^g UNIVERSITY OF PÉCS   (Hungary)

^h MS Hospital   (Ukraine)

ⁱ PARACELSUS MEDICAL UNIVERSITY   (Austria)

^j University Hospital   (Slovenia)

^k CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

^l Department of Neurology   (Slovenia)

^m UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

ⁿ IVAN FRANKO NATIONAL UNIVERSITY OF LVIV   (Ukraine)

^o NATIONAL PIROGOV MEMORIAL MEDICAL UNIVERSITY   (Ukraine)

^p Department of Orthopedics   (Cyprus)

^q BOGOMOLETS NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^r UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^s Faculty of Natural Sciences   (Slovenia)

^t MEDICAL UNIVERSITY OF VIENNA   (Austria)

^u MATER DEI HOSPITAL   (Malta)

^v Institute of Neurology Psychiatry and Narcology   (Ukraine)

^w CHARLES UNIVERSITY   (Czech Republic)

more..

Author keywords

Algorithm; Expert opinion; Fingolimod; Multiple sclerosis; Treatment

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CYCLOPHOSPHAMIDE; FINGOLIMOD; GADOLINIUM; GLATIRAMER; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PEGINTERFERON BETA1A; PLACEBO; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ALGORITHM; ARTHRALGIA; ARTICLE; BINDING AFFINITY; BRAIN SIZE; BRONCHITIS; CARDIOVASCULAR DISEASE; CHILL; DEPRESSION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FEVER; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HUMAN; HYPERTENSION; IMMUNE SYSTEM; IMMUNOMODULATION; INJECTION SITE REACTION; LYMPHOCYTE COUNT; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; MYALGIA; NERVOUS SYSTEM INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PATIENT IDENTIFICATION; PATIENT SELECTION; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; RETINA MACULA EDEMA; RISK REDUCTION; SIDE EFFECT;

EID: 84878794457     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2013.00010     Document Type: Article

References (31)

1. Aktas, O., Küry, P., Kieseier, B., and Hartung, H. P. (2010). Fingolimod is a potential novel therapy for multiple sclerosis. Nat. Rev. Neurol. 6, 373-382.
2. Antel, J., Montalban, X., O'Connor, P., de Vera, A., Cremer, M., Sfikas, N., et al. (2012). Long-term (7-year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Neurology 78, P01.129.
3. Barkhof, F., Cohen, J., Montalbán, X., Comi, G., Zhang-Auberson, L., Holdbrook, F., et al. (2011). Fingolimod (FTY720) reduces volume loss over 12 months compared with intramuscular interferon Beta-1a: subgroup analyses of TRANSFORMS data based on inflammatory disease Activity. European Committee For Treatment and Research in Multiple Sclerosis, Amsterdam, P907.
4. Blahova-Dusankova, J., Kalincik, T., Dolezal, T., Kobelt, G., and Havrdova, E. (2012). Cost of multiple sclerosis in the Czech Republic: the COMS study. Mult. Scler. 18, 662-668.
5. Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., et al. (2012). Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870-1880.
6. Brinkmann, V. (2007). Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol. Ther. 115, 84-105.
7. Brinkmann, V. (2009). FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br. J. Pharmacol. 158, 1173-1182.
8. Chun, J., and Brinkmann, V. (2011). A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov. Med. 12, 213-238.
9. Chun, J., and Hartung, H. P. (2010). Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin. Neuropharmacol. 33, 91-110.
10. Cohen, J. A., Barkhof, F., Comi, G., Hartung, H. P., Khatri, B. O., Montalban, X., et al. (2010a). Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402-415.
11. Cohen, J., Montalban, X., Pelletier, J., Barkhof, F., Comi, G., Hartung, H. P., et al. (2010b). Efficacy and safety of fingolimod in patients switched from intramuscular interferon beta-1a: results of the TRANSFORMS 2-year extension study. ECTRIMS 2010. Mult. Scler. 2010, S289.
12. Devonshire, V., Havrdova, E., Radue, E. W., O'Connor, P., Zhang-Auberson, L., Agoropoulou, C., et al. (2012). Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol. 11, 40-428.
13. Fazekas, F. (2012). Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement oft he Central and East European (CEE) MS Expert Group. Wien. Med. Wochenschr. 162, 354-366.
14. Foster, C. A., Howard, L. M., Schweitzer, A., Persohn, E., Hiestand, P. C., Balatoni, B., et al. (2007). Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J. Pharmacol. Exp. Ther. 323, 469-475.
15. Fox, R., Kappos, L., Cree, B., Kaufman, M., Jeffery, D., Weinstock-Guttman, B., et al. (2011). "Effects of a 24-week natalizumab treatment interruption on clinical and radiologic parameters of multiple sclerosis disease activity: the RESTORE study," in ECTRIMS/ACTRIMS (Medscape Medical News, Oktober 22), Abstr. 150.
16. Francis, G., Kappos, L., O'Connor, P., Collins, W., Zhang-Auberson, L., de Vera, A., et al. (2011). Lymphocytes and fingolimod-temporal pattern and relationship with infections. American Academy of Neurology Meeting April (S30.001), San Diego.
17. Havla, J., Meinl, I., Hohlfeld, R., and Kümpfel, T. (2011). First experiences in multiple sclerosis after switching from natalizumab (Tysabri®) to fingolimod (FTY720, Gilenya®). European Committee for Treatment and Research in Multiple Sclerosis, P 522, Amsterdam.
18. Havrdová, E., Kappos, L., Cohen, J. A., Devonshire, V., Zhang-Auberson, L., Haering, D., et al. (2011). Clinical and magnetic resonance imaging outcomes in subgroups of patients with highly active relapsing-remitting multiple sclerosis treated with fingolimod/FTY720: results from the FREEDOMS and TRANSFORMS phase 3 studies. European Committee for Treatment and Research in Multiple Sclerosis, poster P473, Amsterdam.
19. Johnson, T. A., Shames, I., Keezer, M., Lapierre, Y., Haegert, D. G., Bar-Or, A., et al. (2010). Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients. Clin. Immunol. 137, 15-20.
20. Kappos, L., Arroyo, R., Izquierdo, G., Selmaj, K., Mehling, M., Curovic-Perisic, V., et al. (2011). A controlled study on the effect of fingolimod (FTY720) on the immune response following seasonal influenza vaccination and tetanus toxoid booster injection in patients with multiple sclerosis. European Committee for Treatment and Research in Multiple Sclerosis, P320, Amsterdam.
21. Kappos, L., Radue, E. W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., et al. (2010). A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387-401.
22. Kappos, L., Radue, W.-E., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., et al. (2012). Long-term efficacy and safety of fingolimod (FTY720) in relapsing-remitting multiple sclerosis (RRMS): results from the extension of the phase III FREEDOMS study. Neurology 78, S41. 004.
23. Mäurer, M., Dachsel, R., Domke, S., Ries, S., Reifschneider, G., Friedrich, A., et al. (2011). Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS. Eur. J. Neurol. 18, 1036-1045.
24. Mehling, M., Brinkmann, V., Antel, J., Bar-Or, A., Goebels, N., Vedrine, C., et al. (2008). FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 71, 1261-1267.
25. Mehling, M., Hilbert, P., Fritz, S., Durovic, B., Eichin, D., Gasser, O., et al. (2011). Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann. Neurol. 69, 408-413.
26. Mehling, M., Lindberg, R., Raulf, F., Kuhle, J., Hess, C., Kappos, L., et al. (2010). Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 75, 403-410.
27. O'Connor, P. W., Goodman, A., Kappos, L., Lublin, F. D., Miller, D. H., Polman, C., et al. (2011). Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76, 1858-1865.
28. Pham, T. H., Okada, T., Matloubian, M., Lo, C. G., and Cyster, J. G. (2008). S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity 28, 122-133.
29. Radue, E., de Vera, A., Burtin, P., Holdbrook, F., Francis, G., and Kappos, L. (2010). Fingolimod Reduces Brain Volume Loss in Relapsing-Remitting Multiple Sclerosis (RRMS) Beyond its Anti-inflammatory Activity: Results from FREEDOMS. Toronto: American Academy of Neurology Meeting (Oral Presentation).
30. Rivera, J., Proija, R. L., and Olivera, A. (2008). The alliance of sphingosine 1-phosphate and its receptors in immunity. Nat. Rev. Immunol. 8, 753-782.
31. Spiegel, S., and Milstien, S. (2003). Sphingosine 1-phosphate: an enigmatic signaling lipid. Nat. Rev. Mol. Cell Biol. 4, 397-407.